RELATED STUDY
Key Findings:
Type of Study:
Study Result: Inconclusive
Research Location(s):
Year of Pub:
Cannabinoids Studied:
Chemotype:
Terpenes Studied:
Receptors Studied:
Ligands Studied:
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration:
Cannabinoid Ratio: (THCV) 0 
Dosing Regimen: Δ9-THCV (0.025-2.5 mg/kg)
Clinical Relevance: Δ9-THCV exerts antiepileptiform and anticonvulsant properties and has possible therapeutic application in the treatment of pathophysiologic hyperexcitability states in humans. The mechanism of action is consistent with CB1 receptor activity.
Additional Notes: Pharmacodynamic Study Data
Citation:
